Because our previous studies suggested that use of insulin [22, 23] and/or sulfonylurea [24] are associated with a significantly higher risk of breast cancer, the higher proportions of their use in ever users of rosiglitazone (Table 1) might have only underestimated the beneficial effect of rosiglitazone. This evidence concerns the gene INS and breast cancer.